β-blockers Reverse Agonist-Induced β2-AR Downregulation Regardless of Their Signaling Profile

Sonia Maccari 1,†, Vanessa Vezzi 2,†, Federica Barbagallo 3, Tonino Stati 1, Barbara Ascione 1, Maria Cristina Grò 2, Liviana Catalano 4, Giuseppe Marano 1,*, Paola Matarrese 1, Caterina Ambrosio 2,‡ and Paola Molinari 2,‡

1 Center for Gender-Specific Medicine, National Institute of Health, 00161 Rome, Italy; sonia.maccari@iss.it (S.M.); tonino.stati@iss.it (T.S.); barbara.ascione@iss.it (B.A.); paola.matarrese@iss.it (P.M.)
2 National Center for Drug Research and Evaluation, National Institute of Health, 00161 Rome, Italy; vanessa.vezzi@iss.it (V.V.); mariacristina.gro@iss.it (M.C.G.); caterina.ambrosio@iss.it (C.A.); paola.molinari@iss.it (P.M.)
3 Department of Experimental Medicine, Sapienza University, 00161 Rome, Italy; federica.barbagallo@uniroma1.it
4 National Blood Center, 00161 Rome, Italy; liviana.catalano@iss.it
* Correspondence: giuseppe.marano@iss.it
† These authors contributed equally to this work.
‡ Ambrosio and Molinari should be considered as senior authors.

Received: 25 November 2019; Accepted: 10 January 2020; Published: 14 January 2020

Abstract: Altered β-adrenergic receptor (β-AR) density has been reported in cells, animals, and humans receiving β-blocker treatment. In some cases, β-AR density is upregulated, but in others, it is unaffected or even reduced. Collectively, these results would imply that changes in β-AR density and β-blockade are not related. However, it has still not been clarified whether the effects of β-blockers on receptor density are related to their ability to activate different β-AR signaling pathways. To this aim, five clinically relevant β-blockers endowed with inverse, partial or biased agonism at the β2-AR were evaluated for their effects on β2-AR density in both human embryonic kidney 293 (HEK293) cells expressing exogenous FLAG-tagged human β2-ARs and human lymphocytes expressing endogenous β2-ARs. Cell surface β2-AR density was measured by enzyme-linked immunosorbent assay (ELISA) and flow cytometry. Treatment with propranolol, carvedilol, pindolol, sotalol, or timolol did not induce any significant change in surface β2-AR density in both HEK293 cells and human lymphocytes. On the contrary, treatment with the β-AR agonist isoproterenol reduced the number of cell surface β2-ARs in the tested cell types without affecting β2-AR-mRNA levels. Isoproterenol-induced effects on receptor density were completely antagonized by β-blocker treatment. In conclusion, the agonistic activity of β-blockers does not exert an important effect on short-term regulation of β2-AR density.

Keywords: pharmacology; cell surface receptor density; β-blockers; cultured cells; lymphocytes

1. Introduction

Catecholamines, acting through α- and β-adrenergic receptors, regulate many physiological functions, such as force and frequency of cardiac contraction, vascular and bronchial tone, and metabolism, and are an essential component of the body’s stress response. The tissue responses to catecholamines depend on their relative affinities for receptor adrenergic subtypes, their concentration at the site of the receptor as well as the adrenergic receptor density on target cells. Drugs, such as β-blockers, and clinical disorders, such as heart failure, can alter the number of β-adrenergic receptors (β-AR). Previous studies performed on both animals and humans have reported dissimilar effects...
of β-blocker therapy on β-AR density and sensitivity. Chronic treatment with the β-AR antagonist propranolol significantly increased the number of β-ARs in the heart, lung, and lymphocytes [1–4]. On the contrary, the administration of pindolol, another β₁- and β₂-AR antagonist, resulted in a decrease in the lymphocyte β-AR density [2,3]. Furthermore, treatment with carvedilol, a third-generation β-blocker, was not able to affect myocardial β-AR density in patients with heart failure [5]. Together, these results would imply that changes in receptor density and β-blocking activity of β-blockers are not related. However, it remains to be ascertained whether β-blocker-induced changes in receptor density are related to other pharmacological properties of β-blockers.

Recent findings in the molecular biology of β-ARs show that these receptors can interact with at least two different transduction proteins in the cell membrane: G proteins and β-arrestins. Endogenous agonists of G protein-coupled receptors (GPCRs) are usually equally efficient in promoting G protein-mediated signaling and the interaction of the receptor with arrestins, which promote rapid receptor internalization and signal quenching. However, GPCR ligands, such as β-blockers, can show unequal or divergent molecular efficacies for such interactions. This phenomenon, often called biased agonism or functional ligand selectivity [6], indicates that GPCR ligands do not have a unique profile of efficacy, as previously thought, but can act as agonists or antagonists on distinct transducers, and thus generate a complex pattern of signaling and biological effects. In the present study, we determined whether there is a correlation between the signaling profile of β-blockers and their ability to perturb cell surface β-AR density.

β-ARs (β₁-ARs, β₂-ARs, and β₃-ARs) belong to the GPCR superfamily and activate adenyl cyclase following the binding with catecholamines. β-AR signaling is terminated by phosphorylation of the intracellular domains of the receptor by the family of G protein-coupled receptor kinases. Although both β₁- and β₂-AR couple primarily to Gα and subsequent cyclic adenosine monophosphate (cAMP)-related pathways, they are regulated differently in response to persistent agonist stimulation. In general, the studies in cultured cells indicate that β₁-AR is more resistant to agonist-mediated downregulation than β₂-AR [7–9]. Since β₂-ARs are distributed extensively throughout the body, wherein they mediate the response to sympathetic discharges in many organs and tissues, including immune and central nervous systems [10–12], there is considerable interest in their regulation. At present, an in vitro analysis of the effects of β-blockers with different signaling profiles on β₂-AR density is lacking.

To this aim, five clinically relevant β-blockers endowed with inverse, partial, or biased agonism at the β₂-AR, according to Wisler and colleagues [13], were tested in both human embryonic kidney 293 (HEK293) cells transfected with FLAG-tagged human β₂-ARs and human lymphocytes that express endogenous β₂-ARs. Cell surface β₂-AR density was measured by enzyme-linked immunosorbent assay (ELISA) and flow cytometry using specific antibodies. We found that propranolol, carvedilol, pindolol, sotalol, or timolol do not affect β₂-AR density on their own but reverse agonist-induced β₂-AR downregulation.

2. Results

2.1. β-Blockers Do Not Affect Receptor Density in Simple Cell Systems

To determine the effects of β-blockers on β₂-AR density, we used the HEK293 cell line, stably expressing the N-terminus-FLAG-tagged β₂-AR at a density of 15 pmol/mg of membrane protein as previously reported [14]. A panel of five β-blockers (propanolol, carvedilol, pindolol, sotalol, and timolol) with different efficacy profiles for both cAMP generation and extracellular signal-regulated kinases (ERK) activation, according to the classification suggested by Wisler et al. [13], was used to evaluate β-blocker ability in changing β₂-AR density. Specifically, we tested pindolol, a partial agonist, sotalol, and timolol, two inverse agonists, carvedilol and propranolol, two inverse agonists that also induce ERK activation, i.e., biased agonists [15]. As shown in Figure 1A, no tested β-blocker altered
β2-AR density in HEK293 cells. Furthermore, although propranolol tended to increase β2-AR density no statistical difference was observed among β-blockers (Figure 1A).

![Figure 1](image-url)

**Figure 1.** β-blockers do not affect cell surface β-adrenergic receptor (β2-AR) density. (A) Bar graph showing the effects of β-blockers on cell-surface β2-AR density. HEK293 cells stably expressing the N-terminal-FLAG-β2-AR were treated at 37 °C for 3 h with β-AR antagonists (propranolol (pro), carvedilol (carv), pindolol (pin), sotalolol (sot), timolol (tim)) at the concentration of 1 μM. Treatment with β-AR antagonists did not affect surface β2-AR density. Data are means ± SEM from three independent experiments. (B) β2-AR gene expression in HL-1 cells and peripheral blood lymphocytes was analyzed by real-time polymerase chain reaction (qPCR). β2-AR gene was expressed in both HL-1 cells and peripheral blood lymphocytes. In these cells, β2-AR gene expression was markedly smaller than in the heart. Delta Ct=Ct (gene of interest) – Ct (reference gene); Ct=cycle threshold. *p < 0.05 vs. HL-1 cells; **p < 0.05 vs. HL-1 cells and lymphocytes. (C) Bar graph showing the effects of β-blockers on cell-surface β2-AR density of human lymphocytes. Data are means ± SEM from three independent experiments. (D) Intensified video microscopy analysis after cell staining with anti-β2-AR antibody (green) and counterstained with Hoechst (blue) in HL-1 cells. (E) Cytometric analysis of β2-AR density in HL-1 cells. (left panel) A representative experiment of quantitative evaluation of β2-AR density, after specific immunostaining, using flow cytometric analysis. M stands for median fluorescence intensity (MFI). Dashed line: cells plus isotypic immunoglobulins followed by secondary antibody. (right panel) Bar graph showing cytotoxic results reported as mean ± SEM, from three independent experiments and expressed as a percentage of the value obtained in untreated cells (control).

Given that the regulation of β-ARs expressed by endogenous genes may be more relevant to in vivo receptor regulation, we next evaluated the effects of β-blockers on β2-AR density of endogenous β2-ARs expressed in human lymphocytes. These cells have β2-ARs [15], whose expression level is much lower than in the heart (Figure 1B). Again, no tested β-blocker at the concentration of 1 μM induced any significant change in surface β2-AR density in lymphocytes (Figure 1C).

Since most studies on the effects of β-blockers on receptor density were performed using the β-blocker propranolol [1–4,16,17], we also evaluated the effects of propranolol on the density of endogenous β2-ARs expressed in HL-1 atrial cardiomyocytes derived from mouse AT-1 cells. These cells are currently the only cardiomyocyte cell line available that can be serially passaged while...
maintaining a differentiated cardiac phenotype. Similarly to lymphocytes, HL-1 cells have β2-ARs [18], but their expression level is much lower than in the heart (Figure 1B). Propranolol treatment at the concentration of 1 µM did not induce any significant change in surface β2-AR density in HL-1 cells as determined by static (Figure 1D) and flow cytometry (Figure 1E). Collectively, these results indicate that treatment with β-blockers does not affect short-term regulation of β2-AR density in three different cell types.

2.2. β-Blockers Restore β2-AR Density after Agonist-Induced Receptor Downregulation

Treatment with catecholamines causes β2-AR downregulation. To obtain the maximal receptor downregulation, HEK 293 cells stably expressing the N-terminus-FLAG-tagged β2-AR were incubated in the presence of 1 µM isoproterenol, a synthetic β-AR agonist catecholamine, at 37 °C per 3 h according to a previous study [14]. Approximately 40% of β2-ARs were downregulated in response to isoproterenol stimulation, but, upon adding of β-blockers, internalized receptors completely recycled back to the plasma membrane (Figure 2A). All the tested β-blockers showed equal efficacy in restoring receptor density regardless of their ancillary pharmacological properties.

We next evaluated the effects of the β-AR agonist isoproterenol and β-AR antagonists on β2-AR density in human lymphocytes. Incubation of these cells with isoproterenol (1 µM) for 3 h reduced β2-AR density compared to cells incubated with control medium (Figure 2B). To address the question of whether β-blockers restore β2-AR density in isoproterenol-treated cells, lymphocytes were incubated with isoproterenol for 3 h before adding β-blockers (1 µM) for another 30 min. Coincubation of the cells with isoproterenol and β-blockers (propranolol, carvedilol, pindolol, sotalol, or timolol) completely reversed isoproterenol-mediated β2-AR downregulation restoring surface receptor density (Figure 2B).

We also evaluated the effects of isoproterenol on β2-AR density in HL-1 cardiac cells. We found that treatment with the β-AR agonist isoproterenol reduced the number of cell surface β2-ARs in HL-1 cells as determined by static (Figure 2C) and flow cytometry (Figure 2D). The isoproterenol-induced effects on receptor density were completely antagonized by propranolol treatment (Figure 2C,D). Collectively, these results suggest that β-blockers could exert a class effect in reversing isoproterenol-induced β2-AR downregulation in these simple cellular models.

2.3. Isoproterenol Did Not Affect β2-AR Gene Expression

We performed TaqMan real-time polymerase chain reaction (qPCR) to assess the mRNA levels of β2-ARs in both HL-1 cardiac cells and lymphocytes (Figure 3A). In both cell types, treatment with isoproterenol (1 µM) for 3 h was not able to change β2-AR gene expression (Figure 3B,C). Together, these results suggest that isoproterenol-mediated β2-AR downregulation is not attributable to changes in receptor transcriptional regulation.
Figure 2. β-blockers restore cell surface β2-AR density after agonist-induced receptor downregulation. (A) Bar graph showing the effects of the β2-AR agonist isoproterenol on cell-surface β2-AR density. HEK293 cells stably expressing the N-terminal-FLAG-β2-AR were treated at 37 °C for 3 h with isoproterenol (iso) at the concentration of 1 µM. Isoproterenol caused receptor downregulation. This effect was completely antagonized upon adding β-AR antagonists. Data are means ± SEM from three independent experiments. Abbreviations as in Figure 1. * p < 0.05 vs. all other groups. (B) Bar graph showing the effects of the β2-AR agonist isoproterenol on the cell-surface β2-AR density of human lymphocytes. Isoproterenol caused receptor downregulation, but this effect was completely antagonized upon adding β-AR antagonists. Data are means ± SEM from three independent experiments. Abbreviations as in Figure 1. * p < 0.05 vs. all other groups. (C) Intensified video microscopy analysis after cell staining with anti-β2-AR antibody (green) and counterstained with Hoechst (blue) in HL-1 cells. Isoproterenol reduces β2-AR density, but the addition of propranolol to the culture medium reverses isoproterenol-mediated β2-AR downregulation. (D) Cytometric analysis of β2-AR density in HL-1 cells. Again, isoproterenol reduces β2-AR density, but propranolol antagonizes it. (upper panel) A representative experiment of quantitative evaluation of β2-AR density, after specific immunostaining, using flow cytometric analysis. M stands for median fluorescence intensity (MFI). Dashed line: cells plus isotypic immunoglobulines followed by secondary antibody. (lower panel) Bar graph showing cytofluorimetric results reported as mean ± SEM from three independent experiments and expressed as a percentage of the value obtained in untreated cells (control). * p < 0.05 vs. all other groups.
Figure 3. Isoproterenol does not affect β2-AR mRNA levels in both HL-1 cells and lymphocytes. (A) Representative amplification plot for TaqMan qPCR using the β2-AR assay probe in human lymphocytes (red line, reference gene; green line, β2-AR gene). (B) β2-AR gene expression in HL-1 cells treated with isoproterenol (iso) (1 μM) for 3 h. (C) β2-AR gene expression in lymphocytes treated with isoproterenol (1 μM) for 3 h.

3. Discussion

Regulation of β-AR plasma membrane density is an important process in tuning β-AR response to catecholamines. β-AR antagonists inhibit catecholamine-induced β-AR stimulation and are commonly used to treat a variety of clinical conditions ranging from heart failure to capillary hemangioma. Chronic treatment of humans, animals, or cells with β-blockers may increase, reduce, or even leave the number of β-ARs unchanged depending on the drug used [1–5]. Although chronic adaptations of cardiovascular and sympathetic nervous systems resulting from long-term β-AR blockade can contribute to altered receptor density in animals or humans receiving chronic β-blocker treatment, they do not explain all facets of the problem. Since recent findings in the molecular biology of β-ARs show that β-ARs can interact with G proteins and β-arrestins and that β-blockers can show unequal or divergent molecular efficacies for such interactions, we tested the hypothesis that there is a relation between signaling profile of β-blockers and their ability to perturb cell surface β-AR density. To this aim, five clinically relevant β-blockers endowed with inverse, partial, or biased agonism at the β2-AR were evaluated for their effects on β2-AR density in both cells expressing exogenous FLAG-β2-ARs and cells expressing endogenous β2-ARs. Changes in receptor density were evaluated by immunological techniques, such as ELISA and flow cytometry. Using these techniques and these simple cell systems, we found that this subset of β-blockers does not affect short-term regulation of β2-AR density but is able to reverse agonist-induced β2-AR downregulation.

The results of the present study are in line with those of previous studies that observed no effect of both propranolol and carvedilol on β-AR density in cultured cells. Dangel et al. [19] reported that in H9c2 cardiac cells, propranolol failed to increase receptor density after 24 h of treatment as determined by radioligand binding. Furthermore, Reynolds and Molinoff [20] observed no upregulation of β-ARs in S49 cells by propranolol after 24 h of treatment. Moreover, in cultured chick cardiac myocytes, Asano et al. [21] found that carvedilol itself did not downregulate β-AR density. Conversely, our results
are in contrast to those of some previous studies. Flesch et al. [22] reported that carvedilol, at the concentration of 3 nM, decreased \( \beta \)-ARs in rat cardiomyocytes after 12 h of treatment. Furthermore, Hughes et al. [23] found that propranolol, at concentrations of 10–100 nM, downregulated \( \beta \)-ARs after 16–20 h of treatment of S49 or BC3H-1 cultured cells. Additionally, Reynolds and Molinoff [20] observed that pindolol, at the concentration of 20 nM, decreased total \( \beta \)-ARs in S49 cells after 24 h of treatment. At present, we are unable to explain the discrepancy between our results and those of other studies, although differences in cultured cells, drug concentrations, duration of the treatment, or techniques used for quantification of \( \beta \)-AR density may have contributed to the different results. Furthermore, since some \( \beta \)-AR antagonists have an elevated affinity for \( \beta \)-ARs and are considerably lipophilic, it is possible that the \( \beta \)-blocker is not completely removed during the experiment, thus inhibiting radioligand binding to the receptors by competition during incubation of biological samples with the radioligand and leading to an underestimation of the receptor density. In fact, it has been reported that, after carvedilol incubation of cells or human atrial trabeculae, the affinity of radioligands to \( \beta \)-ARs remained significantly reduced despite extensive efforts to remove carvedilol from receptors [22, 24]. Whether other non-selective high-affinity \( \beta \)-blockers exhibit persistent binding to \( \beta \)-ARs even after washout in cell culture experiments remains to be ascertained. It is emphasized that in our study, receptor surface density was assayed by immunological methods, i.e., immunostaining followed by ELISA or by flow cytometry using a specific antibody that did not have such a disadvantage.

\( \beta \)-ARs are a family of G-protein coupled receptors comprising three subtypes, \( \beta_1 \), \( \beta_2 \), and \( \beta_3 \), which act by activating a Gs protein and adenyl cyclase. \( \beta \)-AR signaling is terminated by phosphorylation of the intracellular domains of the receptor by the family of G protein-coupled receptor kinases. Chronic stimulation of \( \beta_2 \)-ARs by catecholamines causes desensitization of the \( \beta \)-adrenergic system with internalization and reduction of the number of receptors present on the cell surface. In the present study, we found that isoproterenol, a \( \beta \)-AR agonist, decreases \( \beta_2 \)-AR density without affecting \( \beta_2 \)-AR-mRNA levels in three different cells. We also found that \( \beta \)-blocker treatment leads to recycling receptors back to the surface, restoring receptor density, regardless of the ancillary pharmacological properties of \( \beta \)-blockers. These findings confirm and extend previous in vitro results showing the effects of catecholamines on receptor density and the impact of the treatment with the \( \beta \)-blocker propranolol on agonist-induced \( \beta_2 \)-AR downregulation. Di Certo et al. [14] showed that the exposure of cell surface \( \beta_2 \)-ARs to the \( \beta \)-AR agonist isoproterenol resulted in a time-dependent receptor downregulation. This effect was completely abolished by propranolol treatment.

The agonist-induced reduction of \( \beta_2 \)-AR cell surface density is a well-documented phenomenon. In contrast, little is known about the cell surface regulation of the \( \beta_1 \)-AR. Chronic stimulation of \( \beta \)-ARs by catecholamines causes internalization and reduction of the number of both \( \beta_1 \)- and \( \beta_2 \)-ARs present on the cell surface, with the former more resistant to agonist-mediated downregulation than the latter [7–9]. Previous experiments using engineered receptors and cultured cells have demonstrated that treatment with the \( \beta \)-blocker alprenolol is able to antagonize the actions of catecholamines and to restore \( \beta_1 \)-AR density [8]. However, at present, it is unknown whether alprenolol treatment itself is able to regulate \( \beta_1 \)-AR cell surface density in cultured cells.

Additional features of our experiments are worth commenting on. First, studies in humans and animals reported that long-term therapy with \( \beta \)-blockers alters receptor density. In the present study, the exposure of cells to \( \beta \)-AR antagonists lasted only a few hours. Although previous studies show that propranolol fails to increase receptor density after 24 h of treatment, it cannot be ruled out that very prolonged exposures (48–72 h) to \( \beta \)-blockers may influence the transcription and the number of \( \beta \)-ARs. Second, radioligand binding is a powerful and widely used method to quantitatively measure receptor surface density [25, 26]. However, we also know from previous research that there are several technical and logistic challenges associated with this method [27]. Whole-cell ELISA provides a solid alternative to measure surface expression, and agonist-induced GPCR downregulation for N-terminally epitope-tagged receptors expressed in heterologous cells [28, 29]. Third, to evaluate changes in endogenous \( \beta_2 \)-AR density, we used a flow cytometry-based method utilizing a specific
antibody against β2-ARs according to previously reported studies [30,31]. Although flow cytometry is a rapid and reliable method for evaluating changes in receptor density, there are some caveats to consider. In particular, the method may require the optimization of temperature and incubation time to maximize the binding to the receptor, pre-incubation with human serum to decrease Fc binding, and the optimization of methods used for cell dissociation to avoid loss of cell surface epitopes. In addition, high-quality antibodies are needed. In our study, β-AR density changes were induced by very specific ligands. This greatly facilitated the optimization of flow cytometric analyses. Fourth, changes in lymphocyte β2-AR density can also be evaluated using the biotinylated β-AR ligand alprenolol [32]. However, it remains to be determined whether flow cytometric quantification of β2-AR density on blood cells, such as lymphocytes, may be useful to monitor treatment responses, disease activity, and prognosis of diseases involving changes in β-AR density, such as heart failure. Fifth, in the present study, we analyzed the effects of a subset of β-blockers with different signaling profiles on β2-AR density and found that their agonistic activity does not affect short-term regulation of β2-AR density. Since the three β-AR subtypes appear to differ in their distribution as well as their signaling properties, it remains to be determined whether the agonistic activity of β-blockers is able to regulate β1-AR and/or β3-AR cell surface density in cultured cells.

In conclusion, we evaluated the effects of a subset of β-blockers, endowed with varying degrees of G protein/β-arrestin efficacy profile, on β2-AR density and found that no tested β-blocker affected β2-AR density on their own but reversed agonist-induced β2-AR downregulation. Collectively these results suggest that the agonistic activity of β-blockers does not exert an important effect on short-term regulation of β2-AR density.

4. Materials and Methods

4.1. Materials

Isoproterenol, propranolol, pindolol, carvedilol, sotalol, timolol, anti-FLAG monoclonal antibody (M1 clone) and Hoechst 33,258 were from Sigma–Aldrich (St. Louis, MO, USA) while anti-β2-AR antibody from Abcam (Cambridge, UK). Cell culture media, fetal bovine serum, G418, and Lipofectamine were from Invitrogen (Milan, Italy).

4.2. Cell Culture

Human embryonic kidney 293 (HEK 293) cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, GIBCO, Life Technologies, Monza, Italy) supplemented with 10% fetal bovine serum (FBS, GIBCO, Life Technologies, Monza, Italy), 100 units/mL penicillin, 100 µg/mL streptomycin sulfate, and 200 µg/mL G418 (GIBCO, Life Technologies, Monza, Italy) in a humidified atmosphere of 5% CO2 at 37 °C. Cultured cells were serum-starved for 2 h prior to agonist stimulation.

HL-1 cardiac muscle (HL-1) cells were kindly provided by Dr. S. Nanni (Università Cattolica del Sacro Cuore, Rome, Italy) and were cultured in Claycomb medium (Sigma–Aldrich, St. Louis, MO, USA) supplemented with 10% FBS, 0.2 mM norepinephrine, 2 mM L-glutamine, 1 U/mL penicillin, and 1 µg/mL streptomycin solution (Sigma–Aldrich, St. Louis, MO, USA) as previously described [33].

4.3. Isolation of Human Lymphocytes

Three healthy donors (38 ± 3.6 years of age) were recruited for this study at the Institute of Hematology, Sapienza University of Rome (Italy). Following the rules of good medical practice, the nature and purpose of the study were explained to the volunteers who then gave their informed consent. The investigation conforms to the principles outlined in the Declaration of Helsinki. Lymphocytes were isolated from the peripheral blood by centrifugation on a Ficoll/Hypaque density gradient and plastic adherence to deplete monocytes before pharmacological treatments.
4.4. Fluorescence Microscopy

After pharmacological treatments, HL-1 cells were washed in PBS and then stained in ice with an anti-β2-AR antibody (1:100, ab61778, Abcam, Cambridge, UK) for 45 min, following the manufacturer’s instructions. The anti-β2-AR antibody was chosen based on previously reported data [30,31]. After washing, cells were incubated with AlexaFluor 488-conjugated anti-rabbit IgG (Invitrogen Corporation, Milan, Italy) as a secondary antibody for an additional 30 min. At the end of staining, cells were fixed in 2% paraformaldehyde for 15 min, counterstained with Hoechst 33,258 (Sigma–Aldrich, St. Louis, MO, USA) at the concentration of 1 mg/mL in PBS, and then mounted in glycerol/PBS (ratio 1:1, pH 7.4). Images were acquired by intensified video microscopy (IVM) with an Olympus fluorescence microscope (Olympus Corporation, Milan, Italy) equipped with a Zeiss charge-coupled device (CCD) camera (Carl Zeiss, Oberkochen, Germany).

4.5. Flow Cytometry

The effects of β2-AR agonists and antagonists on receptor density were also analyzed using flow cytometry. At the end of pharmacological treatments, human lymphocytes and cardiac HL-1 cells were fixed with 0.01% paraformaldehyde for 10 min to avoid changes in cell surface receptors. After washing in PBS, cells were stained with anti-β2-AR (1:100, ab61778, Abcam, Cambridge, UK) for 45 min, following the manufacturer’s instructions. As mentioned above, the anti-β2-AR antibody was chosen based on previously reported data [29,30]. Next, cells were incubated with AlexaFluor 488-conjugated secondary antibody (Invitrogen Corporation, Milan, Italy) for an additional 30 min. Isotypic immunoglobulines followed by secondary antibody were used as a negative control (rabbit IgG, polyclonal–ab37415, Abcam, Cambridge, UK). Stained cells were analyzed using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) equipped with a 488 argon laser and with a 635 red diode laser. At least 30,000 events per sample were acquired and analyzed using the Cell Quest Pro software (BD Biosciences, San Jose, CA, USA). The median values of fluorescence intensity were used to provide a semi-quantitative evaluation. Changes in receptor density levels were determined as a difference in the fluorescence intensity in control and treated cells.

4.6. Receptor Downregulation and Recycling Assays

HEK293 cells stably expressing the N-terminus-FLAG-tagged β2-AR were incubated in the presence of vehicle (control), propranolol, carvedilol, pindolol, sotalol, timolol, or isoproterenol at the concentration of 1 µM at 37 °C per 3 h. Concentrations of β2-AR ligands were chosen based on results from previous studies [34,35]. Isoproterenol-induced receptor downregulation was reversed by adding 1 µM of the β-blocker to the cells, which were then incubated at 37 °C for an additional hour. The reaction was stopped by fixing the cells with 2% paraformaldehyde in phosphate buffer saline (PBS). Then, the cells were subjected to immune-stained ELISA to quantify the surface receptor density. Briefly, without permeabilization, cells were blocked in 5% nonfat-dried milk in PBS and stained with anti-FLAG-M2-alkaline phosphatase-conjugated antibody (Sigma–Aldrich, St. Louis, MO, USA) at the concentration of 0.1 mg/mL for 1 h at room temperature. The unbound antibody was removed by washing four times with PBS. Next, alkaline phosphatase substrate was added to the cells, and luminescence was immediately read using a plate luminometer (Victorlight, Perkin Elmer, Milan, Italy).

4.7. RNA Isolation and Quantification

Total RNA was extracted from cultured cells and ventricular tissues by using TRIzol (Invitrogen, Monza, Italy) and purified by using an RNA purelink mini kit (Invitrogen, Monza, Italy). The concentration and purity of the RNA solution were determined by using a NanoDrop spectrophotometer (Fisher Scientific, Monza, Italy), whereas its overall quality was analyzed using the Agilent 2100 bioanalyzer with a RNA LabChip (RNA 6000 Nano kit, Agilent, Milan, Italy).
cDNA was obtained using the High Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA, USA). mRNA expression levels of the \( \beta_2 \)-AR were performed using TaqMan gene expression assays (code n. Mm02524224_s1 and Hs00240532_s1 for HL-1 cells and lymphocytes, respectively) (Applied Biosystems, Foster City, CA, USA). qRT-PCR analysis was performed using the 7500 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). The glyceraldehyde 3-phosphate dehydrogenase (GAPDH, code n Mm99999915_g1 and Hs02786624_g1 for HL-1 cells and lymphocytes, respectively) gene was used as a reference gene, and the \( \Delta \)Ct was used for statistical analysis.

4.8. Statistical Analysis

Data are expressed as the mean ± SEM and analyzed using a software program (GraphPad Prism version 5.03, GraphPad Software Inc., San Diego, CA, USA). Statistical significance between different groups was determined by unpaired t-test for two groups or one-way ANOVA with Bonferroni’s post hoc test to compare all pairs of columns for more than two groups. A value of \( p < 0.05 \) was considered statistically significant.

5. Conclusions

In the present study, \( \beta \)-blockers endowed with inverse, partial, or biased agonism at the \( \beta_2 \)-AR were evaluated for their effects on \( \beta_2 \)-AR density in both cells expressing exogenous FLAG-tagged human \( \beta_2 \)-ARs and cells expressing endogenous \( \beta_2 \)-ARs. We found that \( \beta \)-blockers do not affect \( \beta_2 \)-AR density on their own but reverse isoproterenol-induced \( \beta_2 \)-AR downregulation. These results suggest that the agonistic activity of \( \beta \)-blockers does not exert an important effect on short-term regulation of \( \beta_2 \)-AR density.

Author Contributions: Conceptualization, G.M., P.M. (Paola Matarrese), C.A., and P.M. (Paola Molinari); Data curation, V.V., B.A., M.C.G., and L.C.; Formal analysis, S.M., T.S., P.M. (Paola Matarrese), C.A., and P.M. (Paola Molinari); Funding acquisition, G.M. and P.M. (Paola Matarrese); Investigation, S.M., F.B., T.S., B.A., M.C.G., and L.C.; Writing—original draft, G.M., P.M. (Paola Matarrese), C.A., and P.M. (Paola Molinari). All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported in part by grants from the Italian Association for Cancer Research (18526) and Fondazione Peretti to P.M. (Paola Matarrese) and from the Ministero della Salute (02351158) to G.M.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Aarons, R.D.; Molino ff, P.B. Changes in the density of \( \beta \)-adrenergic receptors in rat lymphocytes, heart and lung after chronic treatment with propranolol. *J. Pharmacol. Exp. Ther.* 1982, 221, 439–443. [PubMed]
2. van den Meiracker, A.H.; Man in’t Veld, A.J.; Boomsma, F.; Fischberg, D.J.; Molino ff, P.B.; Schalekamp, M.A. Hemodynamic and \( \beta \)-adrenergic receptor adaptations during long-term \( \beta \)-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. *Circulation* 1989, 80, 903–914. [CrossRef]
3. Hedberg, A.; Gerber, J.G.; Nies, A.S.; Wolfe, B.B.; Molino ff, P.B. Effects of pindolol and propranolol on \( \beta \)-adrenergic receptors on human lymphocytes. *Pharmacol. Exp. Ther.* 1986, 239, 117–123.
4. Michel, M.C.; Pingsmann, A.; Beckeringh, J.J.; Zerkowski, H.R.; Doetsch, N.; Brodde, O.E. Selective regulation of \( \beta \)-1- and \( \beta \)-2-adrenoceptors in the human heart by chronic \( \beta \)-adrenoceptor antagonist treatment. *Br. J. Pharmacol.* 1988, 94, 685–692. [CrossRef][PubMed]
5. Gilbert, E.M.; Abraham, W.T.; Olsen, S.; Hattler, B.; White, M.; Mealy, P.; Larrabee, P.; Bristow, M.R. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. *Circulation* 1996, 94, 2817–2825. [CrossRef]
6. Rajagopal, S.; Kim, J.; Ahn, S.; Craig, S.; Lam, C.M.; Gerard, N.P.; Gerard, C.; Lefkowitz, R.J. Beta-arrestin-but not G protein-mediated signaling by the “decoy” receptor CXCR7. *Proc. Natl. Acad. Sci. USA* 2010, 107, 628–632. [CrossRef]
7. Steinberg, S.F. \( \beta \)-1-adrenergic receptor regulation revisited. *Circ. Res.* 2018, 123, 1199–1201. [CrossRef]
8. Nooh, M.M.; Mancarella, S.; Bahouth, S.W. Novel paradigms governing β1-adrenergic receptor trafficking in primary adult rat cardiac myocytes. Mol. Pharmacol. 2018, 94, 862–875. [CrossRef]

9. Zuckerman, D.M.; Hicks, S.W.; Charron, G.; Hang, H.C.; Machamer, C.E. Differential regulation of two palmitoylation sites in the cytoplasmic tail of the β1-adrenergic receptor. J. Biol. Chem. 2001, 286, 19014–19023. [CrossRef]

10. AlOkda, A.M.; Nasr, M.M.; Amin, S.N. Between an ugly truth and a perfect lie: Wiping off fearful memories using beta-adrenergic receptors antagonists. J. Cell. Physiol. 2019, 234, 5722–5727. [CrossRef]

11. Ciccarelli, M.; Sorrentino, D.; Coscioni, E.; Iaccarino, G.; Santulli, G. Adrenergic Receptors. In Endocrinology of the Heart in Health and Disease; Academic Press: Amsterdam, The Netherlands, 2017; pp. 285–315. [CrossRef]

12. Lorton, D.; Bellinger, D.L. Molecular mechanisms underlying β-adrenergic receptor-mediated cross-talk between sympathetic neurons and immune cells. Int. J. Mol. Sci. 2015, 16, 5635–5665. [CrossRef] [PubMed]

13. Wisler, J.W.; DeWire, S.M.; Whalen, E.J.; Violin, J.D.; Drake, M.T.; Ahn, S.; Shenoy, S.K.; Lefkowitz, R.J. A unique mechanism of beta-blocker action: Carvedilol stimulates beta-arrestin signaling. Proc. Natl. Acad. Sci. USA 2007, 104, 16657–16662. [CrossRef] [PubMed]

14. Di Certo, M.G.; Batassa, E.M.; Casella, I.; Serafino, A.; Floridi, A.; Passananti, C.; Molinari, P.; Mattei, E. Delayed internalization and lack of recycling in a β2-adrenergic receptor fused to the G protein alpha-subunit. BMC Cell. Biol. 2008, 9, 56. [CrossRef] [PubMed]

15. Williams, L.T.; Snyderman, R.; Lefkowitz, R.J. Identification of β-adrenergic receptors in human lymphocytes by [+3H] alprenolol binding. J. Clin. Invest. 1976, 2, 149–155. [CrossRef]

16. Warner, A.L.; Bellah, K.L.; Raya, T.E.; Roeske, W.R.; Goldman, S. Enhanced β2-adrenoceptor density and activation of β2-adrenergic receptor by Rab4 GTPase in cardiac myocytes. J. Biol. Chem. 2005, 280, 11097–11103. [CrossRef]

17. Dangel, V.; Ratge, D.; Wisser, H. Regulation of β-adrenoceptor density and mRNA levels in the rat heart cell-line H9c2. Biochem. J. 1996, 317, 925–931. [CrossRef]

18. Reynolds, E.E.; Molino, P.B. Down regulation of β-adrenergic receptors in S49 lymphoma cells induced by atypical agonists. J. Pharmacol. Exp. Ther. 1986, 239, 654–660.

19. Asano, K.; Zisman, L.S.; Yoshikawa, T.; Headley, V.; Bristow, M.R.; Port, J.D. Bucindolol, a nonselective β1- and β2-adrenergic receptor antagonist, decreases β-adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes. J. Cardiovasc. Pharmacol. 2001, 37, 678–691. [CrossRef]

20. Flesch, M.; EtteUbrück, S.; Rosenkranz, S.; Maack, C.; Cremers, B.; Schlüter, K.D.; Zolk, O.; Böhm, M. Differential effects of carvedilol and metoprolol on isoprenaline-induced changes in β-adrenoceptor density and systolic function in rat cardiac muscle. Cardiovasc. Res. 2001, 49, 371–380. [CrossRef]

21. Hughes, R.J.; Howard, M.J.; Allen, J.M.; Insel, P.A. Decreased β2-adrenergic receptor mRNA expression in receptor-deficient S49 lymphoma cells. Mol. Pharmacol. 1991, 40, 974–979.

22. Kindermann, M.; Maack, C.; Schaller, S.; Finkler, N.; Schmidt, K.I.; Läer, S.; Wuttke, H.; Schäfers, H.J.; Böhm, M. Carvedilol but not metoprolol reduces β-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation 2004, 109, 3182–3190. [CrossRef] [PubMed]

23. Ambrosio, C.; Molinari, P.; Fanelli, F.; Chuman, V.; Sbraccia, M.; Ugor, O.; Costa, T. Different structural requirements for the constitutive and the agonist-induced activities of the beta2-adrenergic receptor. J. Biol. Chem. 2005, 280, 23464–23474. [CrossRef]
28. Makita, N.; Kabasawa, Y.; Otani, Y.; Firman; Sato, J.; Hashimoto, M.; Nakaya, M.; Nishihara, H.; Nangaku, M.; Kurose, H.; et al. Attenuated desensitization of β-adrenergic receptor by water-soluble N-nitrosamines that induce S-nitrosylation without NO release. *Circ. Res.* 2013, 112, 327–334. [CrossRef]

29. Kumari, P.; Srivastava, A.; Banerjee, R.; Ghosh, E.; Gupta, P.; Ranjan, R.; Chen, X.; Gupta, B.; Gupta, C.; Jaiman, D.; et al. Functional competence of a partially engaged GPCR-β-arrestin complex. *Nat. Commun.* 2016, 7, 13416. [CrossRef]

30. Tyurin-Kuzmin, P.A.; Fadeeva, J.I.; Kanareikina, M.A.; Kalinina, N.I.; Sysoева, V.Y.; Dyikanov, D.T.; Stambolsky, D.V.; Tkachuk, V.A. Activation of β-adrenergic receptors is required for elevated α1A-adrenoreceptors expression and signaling in mesenchymal stromal cells. *Sci. Rep.* 2016, 6, 32835. [CrossRef]

31. Tyurin-Kuzmin, P.A.; Dyikanov, D.T.; Fadeeva, J.I.; Sysoeva, V.Y.; Kalinina, N.I. Flow cytometry analysis of adrenoceptors expression in human adipose-derived mesenchymal stem/stromal cells. *Sci. Data* 2018, 5, 180196. [CrossRef]

32. Saygin, D.; Wanner, N.; Rose, J.A.; Naga Prasad, S.V.; Tang, W.H.W.; Erzurum, S.; Asosingh, K. Relative quantification of β-adrenergic receptor in peripheral blood cells using flow cytometry. *Cytometry A* 2018, 93, 563–570. [CrossRef] [PubMed]

33. Claycomb, W.C.; Lanson, N.A., Jr.; Stallworth, B.S.; Egeland, D.B.; Delcarpio, J.B.; Bahinski, A.; Izzo, N.J., Jr. HL-1 cells: A cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. *Proc. Natl. Acad. Sci. USA* 1998, 95, 2979–2984. [CrossRef] [PubMed]

34. Baker, J.G.; Hall, I.P.; Hill, S.J. Agonist and inverse agonist actions of beta-blockers at the human β2-adrenoceptor provide evidence for agonist-directed signaling. *Mol. Pharmacol.* 2003, 64, 1357–1369. [CrossRef] [PubMed]

35. Casella, I.; Ambrosio, C.; Grò, M.C.; Molinari, P.; Costa, T. Divergent agonist selectivity in activating β1- and β2-adrenoceptors for G-protein and arrestin coupling. *Biochem. J.* 2011, 438, 191–202. [CrossRef]